Literature DB >> 18765443

A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.

Yuko Hiruma1, Noriyoshi Kurihara, Mark A Subler, Hua Zhou, Christina S Boykin, Heju Zhang, Seiichi Ishizuka, David W Dempster, G David Roodman, Jolene J Windle.   

Abstract

Paget's disease of bone (PDB) is the second most common bone disease and is characterized by focal bone lesions which contain large numbers of abnormal osteoclasts (OCLs) and very active normal osteoblasts in a highly osteoclastogenic marrow microenvironment. The etiology of PDB is not well understood and both environmental and genetic causes have been implicated in its pathogenesis. Mutations in the SQSTM1/p62 gene have been identified in up to 30% of Paget's patients. To determine if p62 mutation is sufficient to induce PDB, we generated mice harboring a mutation causing a P-to-L (proline-to-leucine) substitution at residue 394 (the murine equivalent of human p62(P392L), the most common PDB-associated mutation). Bone marrow cultures from p62(P394L) mice formed increased numbers of OCLs in response to receptor activator of NF-kappaB ligand (RANKL), tumor necrosis factor alpha (TNF-alpha) or 1alpha,25-(OH)(2)D(3), similar to PDB patients. However, purified p62(P394L) OCL precursors depleted of stromal cells were no longer hyper-responsive to 1alpha,25-(OH)(2)D(3), suggesting effects of the p62(P394L) mutation on the marrow microenvironment in addition to direct effects on OCLs. Co-cultures of purified p62(P394L) stromal cells with either wild-type (WT) or p62(P394L) OCL precursors formed more OCLs than co-cultures containing WT stromal cells due to increased RANKL production by the mutant stromal cells. However, despite the enhanced osteoclastogenic potential of both OCL precursors and marrow stromal cells, the p62(P394L) mice had histologically normal bones. These results indicate that this PDB-associated p62 mutation is not sufficient to induce PDB and suggest that additional factors acting together with p62 mutation are necessary for the development of PDB in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18765443      PMCID: PMC2581430          DOI: 10.1093/hmg/ddn266

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  36 in total

1.  The genetics of Paget's disease of the bone.

Authors:  R J Leach; F R Singer; G D Roodman
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

2.  1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease.

Authors:  C Menaa; J Barsony; S V Reddy; J Cornish; T Cundy; G D Roodman
Journal:  J Bone Miner Res       Date:  2000-02       Impact factor: 6.741

3.  Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.

Authors:  Nancy Laurin; Jacques P Brown; Jean Morissette; Vincent Raymond
Journal:  Am J Hum Genet       Date:  2002-04-30       Impact factor: 11.025

4.  MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells.

Authors:  Carlos Rossa; Kathryn Ehmann; Min Liu; Chetan Patil; Keith L Kirkwood
Journal:  J Interferon Cytokine Res       Date:  2006-10       Impact factor: 2.607

5.  Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL.

Authors:  S D Neale; R Smith; J A Wass; N A Athanasou
Journal:  Bone       Date:  2000-09       Impact factor: 4.398

6.  Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature.

Authors: 
Journal:  J Bone Miner Res       Date:  2000-12       Impact factor: 6.741

7.  Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease.

Authors:  William E Friedrichs; Sakamuri V Reddy; Jan M Bruder; Tim Cundy; Jillian Cornish; Frederick R Singer; G David Roodman
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

8.  Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone.

Authors:  C Menaa; S V Reddy; N Kurihara; H Maeda; D Anderson; T Cundy; J Cornish; F R Singer; J M Bruder; G D Roodman
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

9.  Founder effect in different European countries for the recurrent P392L SQSTM1 mutation in Paget's Disease of Bone.

Authors:  Pui Yan Jenny Chung; Greet Beyens; Núria Guañabens; Steven Boonen; Socrates Papapoulos; Marcel Karperien; Marelise Eekhoff; Liesbeth Van Wesenbeeck; Karen Jennes; Piet Geusens; Erwin Offeciers; Jan Van Offel; Rene Westhovens; Hans Zmierczak; Jean-Pierre Devogelaer; Wim Van Hul
Journal:  Calcif Tissue Int       Date:  2008-06-10       Impact factor: 4.333

10.  Update on the epidemiology of Paget's disease of bone.

Authors:  Cyrus Cooper; Nicholas C Harvey; Elaine M Dennison; Tjeerd P van Staa
Journal:  J Bone Miner Res       Date:  2006-12       Impact factor: 6.741

View more
  36 in total

1.  Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease.

Authors:  Noriyoshi Kurihara; Yuko Hiruma; Kei Yamana; Laëtitia Michou; Côme Rousseau; Jean Morissette; Deborah L Galson; Jumpei Teramachi; Hua Zhou; David W Dempster; Jolene J Windle; Jacques P Brown; G David Roodman
Journal:  Cell Metab       Date:  2011-01-05       Impact factor: 27.287

Review 2.  Selective autophagy mediated by autophagic adapter proteins.

Authors:  Terje Johansen; Trond Lamark
Journal:  Autophagy       Date:  2011-03       Impact factor: 16.016

Review 3.  Role of NF-κB in the skeleton.

Authors:  Deborah Veis Novack
Journal:  Cell Res       Date:  2010-11-16       Impact factor: 25.617

Review 4.  Paget's Disease of Bone.

Authors:  Luigi Gennari; Domenico Rendina; Alberto Falchetti; Daniela Merlotti
Journal:  Calcif Tissue Int       Date:  2019-01-23       Impact factor: 4.333

5.  Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management.

Authors:  Joseph L Shaker
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

6.  Bcl-2 Decreases the Affinity of SQSTM1/p62 to Poly-Ubiquitin Chains and Suppresses the Aggregation of Misfolded Protein in Neurodegenerative Disease.

Authors:  Liang Zhou; Hongfeng Wang; Haigang Ren; Qingsong Hu; Zheng Ying; Guanghui Wang
Journal:  Mol Neurobiol       Date:  2014-10-14       Impact factor: 5.590

7.  p62/sequestosome 1 deficiency accelerates osteoclastogenesis in vitro and leads to Paget's disease-like bone phenotypes in mice.

Authors:  Frank Zach; Franziska Polzer; Alexandra Mueller; André Gessner
Journal:  J Biol Chem       Date:  2018-03-19       Impact factor: 5.157

8.  A quest for clarity in bone erosion: The role of sequestosome 1 in Paget's disease of bone.

Authors:  Megan N Michalski; Bart O Williams
Journal:  J Biol Chem       Date:  2018-06-15       Impact factor: 5.157

9.  Role of ATF7-TAF12 interactions in the vitamin D response hypersensitivity of osteoclast precursors in Paget's disease.

Authors:  Jumpei Teramachi; Yuko Hiruma; Seiichi Ishizuka; Hisako Ishizuka; Jacques P Brown; Laëtitia Michou; Huiling Cao; Deborah L Galson; Mark A Subler; Hua Zhou; David W Dempster; Jolene J Windle; G David Roodman; Noriyoshi Kurihara
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

10.  Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation.

Authors:  Yuko Hiruma; Tadashi Honjo; Diane F Jelinek; Jolene J Windle; Jaekyoon Shin; G David Roodman; Noriyoshi Kurihara
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.